1. Adherence to and effectiveness of lenalidomide after 1 year of treatment in a real world setting. (January 2022) Authors: Santoleri, Fiorenzo; Lasala, Ruggero; Ranucci, Elena; Rocchi, Marco; Pulini, Stefano; Morelli, Anna Maria; Spadano, Antonio; Costantini, Alberto Journal: Journal of oncology pharmacy practice Issue: Volume 28:Number 1(2022) Page Start: 24 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Issue 12 (December 2020) Authors: Tacchetti, Paola; Pantani, Lucia; Patriarca, Francesca; Petrucci, Maria Teresa; Zamagni, Elena; Dozza, Luca; Galli, Monica; Di Raimondo, Francesco; Crippa, Claudia; Boccadoro, Mario; Barbato, Simona; Tosi, Patrizia; Narni, Franco; Montefusco, Vittorio; Testoni, Nicoletta; Spadano, Antonio; Terrag... Journal: Lancet Issue: Volume 7:Issue 12(2020) Page Start: e861 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Issue 12 (December 2021) Authors: Gay, Francesca; Musto, Pellegrino; Rota-Scalabrini, Delia; Bertamini, Luca; Belotti, Angelo; Galli, Monica; Offidani, Massimo; Zamagni, Elena; Ledda, Antonio; Grasso, Mariella; Ballanti, Stelvio; Spadano, Antonio; Cea, Michele; Patriarca, Francesca; D'Agostino, Mattia; Capra, Andrea; Giuliani, Ni... Journal: Lancet oncology Issue: Volume 22:Issue 12(2021) Page Start: 1705 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Prognostic impact of KMT2A‐AFF1‐positivity in 926 BCR‐ABL1‐negative B‐lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996. Issue 9 (9th June 2021) Authors: Piciocchi, Alfonso; Messina, Monica; Elia, Loredana; Vitale, Antonella; Soddu, Stefano; Testi, Anna Maria; Chiaretti, Sabina; Mancini, Marco; Albano, Francesco; Spadano, Antonio; Krampera, Mauro; Bonifacio, Massimiliano; Cairoli, Roberto; Vetro, Calogero; Colella, Florinda; Ferrara, Felicetto; Ci... Journal: American journal of hematology Issue: Volume 96:Issue 9(2021) Page Start: E334 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. TET2 Mutations in Ph-Negative Myeloproliferative Neoplasms: Identification of Three Novel Mutations and Relationship with Clinical and Laboratory Findings. (25th May 2013) Authors: Patriarca, Andrea; Colaizzo, Donatella; Tiscia, Gianluca; Spadano, Raffaele; Di Zacomo, Silvia; Spadano, Antonio; Villanova, Ida; Margaglione, Maurizio; Grandone, Elvira; Dragani, Alfredo Other Names: Arcaini Luca Academic Editor. Journal: BioMed research international Issue: Volume 2013(2013) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗